^
Association details:
| Biomarker: | ER D538G |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | amcenestrant (SAR439859) (Selective estrogen receptor degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
277MO - SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in ER+/ HER2- metastatic breast cancer (mBC): Biomarker analyses from a phase I/II study
Published date:
09/18/2020
Excerpt:
...heavily pretreated postmenopausal pts with ER+/HER2- mBC who received SAR439859 monotherapy...ESR1 muts most commonly detected at BL and EOT were D538G, Y537S and Y537N. ESR1 muts in cfDNA at BL and OT were assessed by droplet digital polymerase chain reaction (ddPCR). SAR439859 showed clinical benefit (complete response + partial response [PR] + stable disease ≥24 weeks) in 40% (12/30) of WT ESR1 pts and 32% (9/28) of mutated ESR1 pts, per ddPCR.
Trial ID:
